Multimeric Biotherapeutics, Inc.
2011 News Dec. 22, 2011: Multimeric Biotherapeutics, Inc. receives an exclusive license to all animal health and reagent uses of its patented multimeric TNF Superfamily ligands Oct. 28, 2011: Topotarget A/S grants Multimeric Biotherapeutics, Inc. an exclusive license to the MegaLigand Platform of TNF Superfamily ligands Aug. 1, 2011: Multimeric Biotherapeutics, Inc. relocates its laboratories to the San Diego Science Center Apr. 25, 2011: Multimeric Biotherapeutics, Inc. obtains an exclusive license to highly active forms of the TNF SuperFamily (TNFSF) molecules using the UltraLigand™ multimerization technology 2010 News Nov. 15, 2010: Multimeric Biotherapeutics receives Stimulus funding from the U.S. Government's QTDP program Apr. 24, 2010: Multimeric Biotherapeutics receives a NIDA grant to develop an innovative nicotine vaccine Apr. 12, 2010: Multimeric Biotherapeutics to present at 2010 BIO International Convention 2009 News Oct. 12, 2009: Preclinical study of Multimeric Biotherapeutic's lead molecule published by PLoS ONE Oct. 8, 2009: VIDEO of Marc Hertz, CEO of Multimeric Biotherapeutics, at the Quick Pitch competition Oct. 1, 2009: Multimeric Biotherapeutics selected to present at Tech Coast Angels' Quick Pitch competition Aug. 24, 2009: Multimeric Biotherapeutics selected to present at BIOCOM Investor Conference Jul. 22, 2009: Multimeric Biotherapeutics announces the issuance of a key patent in Europe 2008 News Dec. 7, 2008: Biotech veteran Marc Hertz becomes CEO of Multimeric Biotherapeutics, Inc. Oct. 1, 2008: Richard Kornbluth becomes Chief Scientific Officer of Multimeric Biotherapeutics, Inc. Feb. 19, 2008: Second US Patent issues for Multimeric Biotherapeutics's lead program Feb. 8, 2008: San Diego company Multimeric Biotherapeutics, Inc. formed as a Delaware C Corp.
